These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15051746)

  • 41. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
    Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
    Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ximelagatran: an oral direct thrombin inhibitor.
    Dager WE; Vondracek TG; McIntosh BA; Nutescu EA
    Ann Pharmacother; 2004 Nov; 38(11):1881-97. PubMed ID: 15383641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety.
    Kamali F; Wood P; Ward A
    Ann Hematol; 2009 Feb; 88(2):141-9. PubMed ID: 18716776
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biliary excretion of ximelagatran and its metabolites and the influence of erythromycin following intraintestinal administration to healthy volunteers.
    Matsson EM; Eriksson UG; Knutson L; Hoffmann KJ; Logren U; Fridblom P; Petri N; Lennernäs H
    J Clin Pharmacol; 2011 May; 51(5):770-83. PubMed ID: 20663994
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs.
    Sjödin E; Fritsch H; Eriksson UG; Logren U; Nordgren A; Forsell P; Knutson L; Lennernäs H
    Drug Metab Dispos; 2008 Aug; 36(8):1519-28. PubMed ID: 18458048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug.
    Clement B; Lopian K
    Drug Metab Dispos; 2003 May; 31(5):645-51. PubMed ID: 12695354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
    Sarich TC; Wolzt M; Eriksson UG; Mattsson C; Schmidt A; Elg S; Andersson M; Wollbratt M; Fager G; Gustafsson D
    J Am Coll Cardiol; 2003 Feb; 41(4):557-64. PubMed ID: 12598065
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
    Eriksson H; Eriksson UG; Frison L; Hansson PO; Held P; Holmström M; Hägg A; Jonsson T; Lapidus L; Leijd B; Stockelberg D; Säfwenberg U; Taghavi A; Thorsén M
    Thromb Haemost; 1999 Mar; 81(3):358-63. PubMed ID: 10102460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea.
    Kim BH; Yi S; Kim J; Lim KS; Kim KP; Lee B; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Jun; 31(6):1234-43. PubMed ID: 19695390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran.
    Carlsson SC; Schulman S
    Semin Vasc Med; 2005 Aug; 5(3):259-65. PubMed ID: 16123913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Orally active direct thrombin inhibitors.
    Weitz J
    Semin Vasc Med; 2003 May; 3(2):131-8. PubMed ID: 15199476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.
    Cullberg M; Eriksson UG; Wåhlander K; Eriksson H; Schulman S; Karlsson MO
    Clin Pharmacol Ther; 2005 Apr; 77(4):279-90. PubMed ID: 15903126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
    Johansson S; Wåhlander K; Larson G; Ohlsson L; Larsson M; Eriksson UG
    Blood Coagul Fibrinolysis; 2003 Oct; 14(7):677-84. PubMed ID: 14517494
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ximelagatran: a new oral anticoagulant.
    Francis CW
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):139-52. PubMed ID: 15171963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
    Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
    [TBL] [Abstract][Full Text] [Related]  

  • 58. No effect of encapsulation on the pharmacokinetics of warfarin.
    Johansson S; Ohlsson L; Stenhoff H; Wåhlander K; Cullberg M
    Biopharm Drug Dispos; 2005 Apr; 26(3):121-7. PubMed ID: 15751004
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Results of THRIVE treatent study show that ximelagatran is safe and effective against throbosis.
    J Support Oncol; 2004; 2(1):56. PubMed ID: 15330373
    [No Abstract]   [Full Text] [Related]  

  • 60. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.